[Ip-health] New Tufts study on R&D costs

Ruth Lopert ruth.lopert at gmail.com
Fri Nov 14 15:28:10 PST 2014


I'm going with 2.1bn

On Sat, Nov 15, 2014 at 5:11 AM, Outterson, Kevin <mko at bu.edu> wrote:

> very good point on cost of capital for Gilead.  More bond data across the
> industry would be interesting.
>
> Kevin
> ___________________
> Professor of Law & N. Neal Pike Scholar in Health and Disability Law -
> Boston University
> Associate Fellow, Chatham House
> Editor in Chief, Journal of Law, Medicine & Ethics<http://www.aslme.org/>
> Blogging health law at The Incidental Economist<
> http://www.theincidentaleconomist.com/>
> Research papers at SSRN<http://ssrn.com/author=340746> & Google Scholar<
> http://scholar.google.com/citations?user=m4to2LMAAAAJ&hl=en>
> @koutterson | 617 935 6517
>
> On Nov 14, 2014, at 4:14 PM, Jamie Love <james.love at keionline.org<mailto:
> james.love at keionline.org>> wrote:
>
> It will be interesting to see what "cost of capital" figures Tufts uses
> this year.
>
> Recently Gilead priced a series of bonds, $500 million at $2.35 percent
> maturing February 2020, $1,750M at 3.5 percent maturing February 2025 and
> $1,750M at 4.5 percent maturing February 2045.
>
>
>
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>



More information about the Ip-health mailing list